Evidence map›Paper›PMID 30627778›Full record

SynthesisSkeletal radiology2019

Thermal ablation to relieve pain from metastatic bone disease: a systematic review.

Nicolò Gennaro, Luca Maria Sconfienza, Federico Ambrogi, Sara Boveri, Ezio Lanza

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Skeletal radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Palliative Arterial Embolization for Metastases of the Sternum.Cardiovascular and interventional radiology · 2023
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. CIRSE Standards of Practice on Thermal Ablation of Bone Tumours.Cardiovascular and interventional radiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Nicolò GennaroSpecialization School in Radiology, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Italy. nicolo.gennaro@st.hunimed.eu.ORCID http://orcid.org/0000-0001-7259-6980
Luca Maria SconfienzaUnità Operativa di Radiologia Diagnostica e Interventistica, IRCCS Istituto Ortopedico Galeazzi, 20161 Milano, Italy.
Federico AmbrogiDepartment of Clinical Sciences and Community Health, University of Milan, 20122 Milano, Italy.
Sara BoveriDirezione Scientifica, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy.
Ezio LanzaDipartimento di Radiologia Diagnostica e Interventistica, Humanitas Research Hospital, Rozzano, Italy.
University of Milan · ITHumanitas University · ITIRCCS Humanitas Research Hospital · ITIRCCS Policlinico San Donato · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo review the efficacy of percutaneous thermal ablation (TA) of bone metastases (radiofrequency ablation [RFA], microwave ablation [MWA], cryoablation [CA], and MR-guided focused ultrasound [MRgFUS]) in reducing pain in patients with advanced stage cancer. MATERIALS AND

methodsWe searched MEDLINE/PubMed, MEDLINE In-Process, BIDS ISI, Embase, CINAHL, and the Cochrane database using the keywords "ablation," "painful," "bone," and "metastases" combined in multiple algorithms. Inclusion criteria were: original clinical studies published between 2001 and 2018; performance of RFA, MWA, CA or MRgFUS; and quantitative pain assessment before/after TA of bone metastasis.

resultsEleven papers (3 on RFA, 1 on MWA, 2 on CA, and 5 on MRgFUS) involving 364 patients were reviewed. A technical success rate of 96-100% was reported, with follow-up for up to 6 months. At baseline, pain scores ranged from 5.4 to 8, at 1-4 weeks from 0.5 to 5, and at 12 weeks from 0.3 to 4.5. Mean pain reduction compared with baseline ranged from 26 to 91% at 4 weeks and from 16% to 95% at 12 weeks. MWA treatments caused no complications, whereas MRgFUS showed the highest complication rate. The number of minor complications observed ranged from 0 to 59 (complication ratio 0-1.17), whereas the number of significant adverse effects ranged from 0 to 4 (complication ratio 0-0.04).

conclusionAll techniques achieved pain relief after 1 and 3 months, in up to 91% and 95% of patients respectively. MWA showed a negligible complication rate, whereas MRgFUS is associated with a noteworthy rate of adverse events. Future studies should adopt a standardized pain reporting scale to allow for meta-analysis.

Indexed as

Ablation TechniquesBone NeoplasmsCancer PainHumansMusculoskeletal PainAblationBoneCryoablationFocused ultrasoundMetastasisMicrowavePainRadiofrequency

Identifiers

PMID30627778
OpenAlexW2910544138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.